Insider · CIK 0001789545

Scalzo Richard William

Reports to the SEC for 3 companies · WALTHAM, MA

sec.gov

Transactions

Companies

Filings

CIK

0001789545

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-09-16	CBIOCRESCENT BIOPHARMA, INC.S Sale	Chief Financial Officer	SSale	−568 sh	$17.90	−$10.2K	19,730
2026-06-22	CBIOCRESCENT BIOPHARMA, INC.S Sale	Chief Financial Officer	SSale	−1,112 sh	$17.99	−$20K	20,298
2025-12-15	CBIOCRESCENT BIOPHARMA, INC.A Award	Chief Financial Officer	AAward	+14.4K sh	—	—	14,422
2025-12-15	CBIOCRESCENT BIOPHARMA, INC.A Award	Chief Financial Officer	AAward	+5,000 sh	—	—	19,422
2025-12-15	CBIOCRESCENT BIOPHARMA, INC. · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+57.7K sh	—	—	57,688
2025-03-11	DYNDyne Therapeutics, Inc.S Sale	SVP, Head of Finance & Admin.	SSale	−1,343 sh	$11.38	−$15.3K	122,330
2025-03-05	DYNDyne Therapeutics, Inc.S Sale	SVP, Head of Finance & Admin.	SSale	−917 sh	$11.83	−$10.8K	123,673
2025-02-18	DYNDyne Therapeutics, Inc.S Sale	SVP, Head of Finance & Admin.	SSale	−2,488 sh	$13.95	−$34.7K	124,590
2024-12-11	DYNDyne Therapeutics, Inc.S Sale	SVP, Head of Finance & Admin.	SSale	−1,455 sh	$28.12	−$40.9K	127,078
2024-12-04	DYNDyne Therapeutics, Inc.A Award	SVP, Head of Finance & Admin.	AAward	+32.7K sh	—	—	128,533
2024-12-04	DYNDyne Therapeutics, Inc. · Stock option (right to buy)A Award	SVP, Head of Finance & Admin.	AAward	+52.3K sh	—	—	52,300
2024-11-18	DYNDyne Therapeutics, Inc.S Sale	SVP, Head of Finance & Admin.	SSale	−2,735 sh	$28.20	−$77.1K	95,833
2024-09-18	DYNDyne Therapeutics, Inc.S Sale	SVP, Head of Finance & Admin.	SSale	−1,390 sh	$34.55	−$48K	98,568
2024-09-11	DYNDyne Therapeutics, Inc.S Sale	SVP, Head of Finance & Admin.	SSale	−1,468 sh	$31.89	−$46.8K	99,958
2024-09-06	DYNDyne Therapeutics, Inc.M Exercise/Conversion	SVP, Head of Finance & Admin.	MExercise/Conversion	+6,502 sh	$5.54	+$36K	117,524
2024-09-06	DYNDyne Therapeutics, Inc.M Exercise/Conversion	SVP, Head of Finance & Admin.	MExercise/Conversion	+3,353 sh	$5.54	+$18.6K	120,877
2024-09-06	DYNDyne Therapeutics, Inc.M Exercise/Conversion	SVP, Head of Finance & Admin.	MExercise/Conversion	+34.8K sh	$19.00	+$662K	155,710
2024-09-06	DYNDyne Therapeutics, Inc.M Exercise/Conversion	SVP, Head of Finance & Admin.	MExercise/Conversion	+16.7K sh	$13.12	+$219K	172,406
2024-09-06	DYNDyne Therapeutics, Inc.M Exercise/Conversion	SVP, Head of Finance & Admin.	MExercise/Conversion	+29.8K sh	$8.58	+$256K	202,198
2024-09-06	DYNDyne Therapeutics, Inc.M Exercise/Conversion	SVP, Head of Finance & Admin.	MExercise/Conversion	+18.8K sh	$10.72	+$201K	220,948
2024-09-06	DYNDyne Therapeutics, Inc.M Exercise/Conversion	SVP, Head of Finance & Admin.	MExercise/Conversion	+6,552 sh	$10.88	+$71.3K	227,500
2024-09-06	DYNDyne Therapeutics, Inc.S Sale	SVP, Head of Finance & Admin.	SSale	−124K sh	$32.14	−$4M	103,126
2024-09-06	DYNDyne Therapeutics, Inc.S Sale	SVP, Head of Finance & Admin.	SSale	−1,700 sh	$32.63	−$55.5K	101,426
2024-09-06	DYNDyne Therapeutics, Inc. · Stock option (right to buy)M Exercise/Conversion	SVP, Head of Finance & Admin.	MExercise/Conversion	−6,502 sh	—	—	0
2024-09-06	DYNDyne Therapeutics, Inc. · Stock option (right to buy)M Exercise/Conversion	SVP, Head of Finance & Admin.	MExercise/Conversion	−3,353 sh	—	—	0
2024-09-06	DYNDyne Therapeutics, Inc. · Stock option (right to buy)M Exercise/Conversion	SVP, Head of Finance & Admin.	MExercise/Conversion	−34.8K sh	—	—	742
2024-09-06	DYNDyne Therapeutics, Inc. · Stock option (right to buy)M Exercise/Conversion	SVP, Head of Finance & Admin.	MExercise/Conversion	−16.7K sh	—	—	8,348
2024-09-06	DYNDyne Therapeutics, Inc. · Stock option (right to buy)M Exercise/Conversion	SVP, Head of Finance & Admin.	MExercise/Conversion	−29.8K sh	—	—	25,208
2024-09-06	DYNDyne Therapeutics, Inc. · Stock option (right to buy)M Exercise/Conversion	SVP, Head of Finance & Admin.	MExercise/Conversion	−18.8K sh	—	—	26,250
2024-09-06	DYNDyne Therapeutics, Inc. · Stock option (right to buy)M Exercise/Conversion	SVP, Head of Finance & Admin.	MExercise/Conversion	−6,552 sh	—	—	28,394
2024-08-19	DYNDyne Therapeutics, Inc.S Sale	SVP, Head of Finance & Admin.	SSale	−2,442 sh	$45.01	−$110K	111,332
2024-08-19	DYNDyne Therapeutics, Inc.S Sale	SVP, Head of Finance & Admin.	SSale	−310 sh	$46.00	−$14.3K	111,022
2024-06-11	DYNDyne Therapeutics, Inc.S Sale	SVP, Head of Finance & Admin.	SSale	−1,331 sh	$31.34	−$41.7K	113,774
2024-06-10	DYNDyne Therapeutics, Inc.S Sale	SVP, Head of Finance & Admin.	SSale	−1,590 sh	$30.23	−$48.1K	115,105
2024-05-16	DYNDyne Therapeutics, Inc.S Sale	SVP, Head of Finance & Admin.	SSale	−2,126 sh	$28.20	−$60K	117,157
2024-05-16	DYNDyne Therapeutics, Inc.S Sale	SVP, Head of Finance & Admin.	SSale	−462 sh	$28.59	−$13.2K	116,695
2024-03-11	DYNDyne Therapeutics, Inc.S Sale	SVP, Head of Finance & Admin.	SSale	−1,082 sh	$25.70	−$27.8K	120,873
2024-03-11	DYNDyne Therapeutics, Inc.S Sale	SVP, Head of Finance & Admin.	SSale	−1,590 sh	$24.99	−$39.7K	119,283
2024-03-08	DYNDyne Therapeutics, Inc.M Exercise/Conversion	SVP, Head of Finance & Admin.	MExercise/Conversion	+68.9K sh	$5.54	+$382K	190,874
2024-03-08	DYNDyne Therapeutics, Inc.M Exercise/Conversion	SVP, Head of Finance & Admin.	MExercise/Conversion	+17.3K sh	$5.54	+$96K	208,207
2024-03-08	DYNDyne Therapeutics, Inc.S Sale	SVP, Head of Finance & Admin.	SSale	−30.8K sh	$25.31	−$778K	177,452
2024-03-08	DYNDyne Therapeutics, Inc.S Sale	SVP, Head of Finance & Admin.	SSale	−55.2K sh	$26.72	−$1.48M	122,244
2024-03-08	DYNDyne Therapeutics, Inc.S Sale	SVP, Head of Finance & Admin.	SSale	−289 sh	$27.33	−$7,898.37	121,955
2024-03-08	DYNDyne Therapeutics, Inc. · Stock option (right to buy)M Exercise/Conversion	SVP, Head of Finance & Admin.	MExercise/Conversion	−68.9K sh	—	—	9,855
2024-03-08	DYNDyne Therapeutics, Inc. · Stock option (right to buy)M Exercise/Conversion	SVP, Head of Finance & Admin.	MExercise/Conversion	−17.3K sh	—	—	0
2024-03-07	DYNDyne Therapeutics, Inc.S Sale	SVP, Head of Finance & Admin.	SSale	−2,273 sh	$25.85	−$58.8K	121,955
2024-03-01	DYNDyne Therapeutics, Inc.M Exercise/Conversion	SVP, Head of Finance & Admin.	MExercise/Conversion	+9,311 sh	$1.03	+$9,590.33	133,539
2024-03-01	DYNDyne Therapeutics, Inc.S Sale	SVP, Head of Finance & Admin.	SSale	−8,747 sh	$28.22	−$247K	124,792
2024-03-01	DYNDyne Therapeutics, Inc.S Sale	SVP, Head of Finance & Admin.	SSale	−564 sh	$28.65	−$16.2K	124,228
2024-03-01	DYNDyne Therapeutics, Inc. · Stock option (right to buy)M Exercise/Conversion	SVP, Head of Finance & Admin.	MExercise/Conversion	−9,311 sh	—	—	0

Recent filings

Accepted (ET)
Sep 184
Scalzo Richard William0001628280-26-062705
SEC(opens sec.gov)
Jun 234
Scalzo Richard William0001628280-26-044890
SEC(opens sec.gov)
Dec 174
Scalzo Richard William0001628280-25-057681
SEC(opens sec.gov)
Mar 134
Scalzo Richard William0000950170-25-038731
SEC(opens sec.gov)
Mar 74
Scalzo Richard William0000950170-25-035490
SEC(opens sec.gov)
Feb 184
Scalzo Richard William0000950170-25-022455
SEC(opens sec.gov)
Dec 114
Scalzo Richard William0000950170-24-135570
SEC(opens sec.gov)
Dec 64
Scalzo Richard William0000950170-24-134075
SEC(opens sec.gov)
Nov 184
Scalzo Richard William0000950170-24-127992
SEC(opens sec.gov)
Sep 194
Scalzo Richard William0000950170-24-108153
SEC(opens sec.gov)
Sep 114
Scalzo Richard William0000950170-24-105515
SEC(opens sec.gov)
Sep 104
Scalzo Richard William0000950170-24-105123
SEC(opens sec.gov)

Companies

Address

C/O CRESCENT BIOPHARMA, INC. 300 FIFTH AVENUE

WALTHAM, MA, 02451